253 related articles for article (PubMed ID: 35291561)
41. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH.
Prasad H; Rao R
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6640-E6649. PubMed ID: 29946028
[TBL] [Abstract][Full Text] [Related]
42. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
[TBL] [Abstract][Full Text] [Related]
43. Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models.
Huang Y
Biochem Soc Trans; 2011 Aug; 39(4):924-32. PubMed ID: 21787325
[TBL] [Abstract][Full Text] [Related]
44. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
Hu J; Liu CC; Chen XF; Zhang YW; Xu H; Bu G
Mol Neurodegener; 2015 Mar; 10():6. PubMed ID: 25871773
[TBL] [Abstract][Full Text] [Related]
45. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier.
Bachmeier C; Paris D; Beaulieu-Abdelahad D; Mouzon B; Mullan M; Crawford F
Neurodegener Dis; 2013; 11(1):13-21. PubMed ID: 22572854
[TBL] [Abstract][Full Text] [Related]
46. ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing Aβ impairment of insulin signaling in an Alzheimer's disease mouse model.
Chan ES; Shetty MS; Sajikumar S; Chen C; Soong TW; Wong BS
Sci Rep; 2016 May; 6():26119. PubMed ID: 27189808
[TBL] [Abstract][Full Text] [Related]
47. ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum.
Belinson H; Michaelson DM
J Neural Transm (Vienna); 2009 Nov; 116(11):1427-34. PubMed ID: 19370389
[TBL] [Abstract][Full Text] [Related]
48. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.
Fernández-Calle R; Konings SC; Frontiñán-Rubio J; García-Revilla J; Camprubí-Ferrer L; Svensson M; Martinson I; Boza-Serrano A; Venero JL; Nielsen HM; Gouras GK; Deierborg T
Mol Neurodegener; 2022 Sep; 17(1):62. PubMed ID: 36153580
[TBL] [Abstract][Full Text] [Related]
49. Apolipoprotein E4 inhibits γ-secretase activity via binding to the γ-secretase complex.
Sun Y; Islam S; Gao Y; Nakamura T; Zou K; Michikawa M
J Neurochem; 2023 Mar; 164(6):858-874. PubMed ID: 36582176
[TBL] [Abstract][Full Text] [Related]
50. Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease.
Nakamura T; Kawarabayashi T; Ueda T; Shimomura S; Hoshino M; Itoh K; Ihara K; Nakaji S; Takatama M; Ikeda Y; Shoji M
J Alzheimers Dis; 2023; 93(1):333-348. PubMed ID: 36970894
[TBL] [Abstract][Full Text] [Related]
51. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis.
Uddin MS; Kabir MT; Al Mamun A; Abdel-Daim MM; Barreto GE; Ashraf GM
Mol Neurobiol; 2019 Apr; 56(4):2450-2465. PubMed ID: 30032423
[TBL] [Abstract][Full Text] [Related]
52. ApoE4 activates C/EBPβ/δ-secretase with 27-hydroxycholesterol, driving the pathogenesis of Alzheimer's disease.
Wang ZH; Xia Y; Liu P; Liu X; Edgington-Mitchell L; Lei K; Yu SP; Wang XC; Ye K
Prog Neurobiol; 2021 Jul; 202():102032. PubMed ID: 33716161
[TBL] [Abstract][Full Text] [Related]
53. Human apolipoprotein E ɛ4 expression impairs cerebral vascularization and blood-brain barrier function in mice.
Alata W; Ye Y; St-Amour I; Vandal M; Calon F
J Cereb Blood Flow Metab; 2015 Jan; 35(1):86-94. PubMed ID: 25335802
[TBL] [Abstract][Full Text] [Related]
54. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis.
Mahan TE; Wang C; Bao X; Choudhury A; Ulrich JD; Holtzman DM
Mol Neurodegener; 2022 Feb; 17(1):13. PubMed ID: 35109920
[TBL] [Abstract][Full Text] [Related]
55. Apolipoprotein E and Alzheimer's Disease: Findings, Hypotheses, and Potential Mechanisms.
Koutsodendris N; Nelson MR; Rao A; Huang Y
Annu Rev Pathol; 2022 Jan; 17():73-99. PubMed ID: 34460318
[TBL] [Abstract][Full Text] [Related]
56. Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition.
Johnson NR; Wang AC; Coughlan C; Sillau S; Lucero E; Viltz L; Markham N; Allen C; Dhanasekaran AR; Chial HJ; Potter H
Alzheimers Res Ther; 2022 Jun; 14(1):88. PubMed ID: 35768831
[TBL] [Abstract][Full Text] [Related]
57. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease.
Cerf E; Gustot A; Goormaghtigh E; Ruysschaert JM; Raussens V
FASEB J; 2011 May; 25(5):1585-95. PubMed ID: 21266538
[TBL] [Abstract][Full Text] [Related]
58. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease.
Butterfield DA; Mattson MP
Neurobiol Dis; 2020 May; 138():104795. PubMed ID: 32036033
[TBL] [Abstract][Full Text] [Related]
59. Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease.
Martiskainen H; Haapasalo A; Kurkinen KM; Pihlajamäki J; Soininen H; Hiltunen M
Expert Opin Ther Targets; 2013 Jul; 17(7):781-94. PubMed ID: 23573918
[TBL] [Abstract][Full Text] [Related]
60. Human apolipoprotein E4 accelerates beta-amyloid deposition in APPsw transgenic mouse brain.
Carter DB; Dunn E; McKinley DD; Stratman NC; Boyle TP; Kuiper SL; Oostveen JA; Weaver RJ; Boller JA; Gurney ME
Ann Neurol; 2001 Oct; 50(4):468-75. PubMed ID: 11601499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
